Robert N. Page

Avicanna Completes First Commercial Export of CBG Into the European Union

Retrieved on: 
Friday, December 24, 2021
Aureus, National Organ Transplant Act of 1984, RHO, Systematic review, LinkedIn, Prospectus, Twitter, Seed, Leadership, Bulk, Inflammatory bowel disease, Fair Debt Collection Practices Act, GLOBE, S, TSX, Absorption, Effect, Patent, Arthritis, Robert N. Page, Compliance, SEDAR, Frontiers, Dermatology, Company, Cannabidiol, Social media, THC, Instagram, Czech Republic, Perception, Therapy, Solution, Facebook, National Organic Program, MaRS Discovery District, Lists of diseases, Wellness, Microbiology, Streptococcus mutans, Rock (geology), United States Department of Agriculture, FSE, Cannabis, News, Luigi Borrelli, Chronic pain, Pharmacology, Union, CBG, Research, Risk, International, Fine chemical, Pharmaceutical industry, Bookkeeping, Romano, CBD, Cannabinoid, Cannabigerol

TORONTO, Dec. 24, 2021 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. (“SMGH”), it has expanded reach for its Aureus raw materials in the European Union with a commercial export of purified cannabigerol (“CBG”) into the Czech Republic.

Key Points: 
  • (SMGH), it has expanded reach for its Aureus raw materials in the European Union with a commercial export of purified cannabigerol (CBG) into the Czech Republic.
  • The completed export into the Czech Republic marks the Companys first commercial export of CBG into the European Union and the twelfth (12th) market that the Aureus branded products has entered.
  • CBG is typically expressed in low amounts in common cultivars of cannabis, however, Avicanna has propagated proprietary cultivars that expresses exceptionally high amounts of the rare cannabinoid.
  • CBG also has the potential to be formulated across various delivery forms including topical and ingestible for a given therapeutic focus.